Fusion Taper System
K201047 · Signature Orthopaedics Pty, Ltd. · LZO · Apr 16, 2021 · Orthopedic
Device Facts
| Record ID | K201047 |
| Device Name | Fusion Taper System |
| Applicant | Signature Orthopaedics Pty, Ltd. |
| Product Code | LZO · Orthopedic |
| Decision Date | Apr 16, 2021 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3353 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
Signature Orthopaedics' Fusion Taper System is intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for: - . Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis - . Inflammatory joint disease including rheumatoid arthritis - . Correction of functional deformity including congenital hip dysplasia - . Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture - . Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemi-arthroplasty, surface replacement, or total replacement Signature Orthopaedics' Fusion Taper System is intended for cementless fixation only.
Device Story
Modular hip prosthesis system comprising femoral heads and taper sleeves; used in total hip arthroplasty. Device components connect to femoral stems via 12/14 inner and 16/18 outer tapers. Intended for surgical implantation by orthopedic surgeons in clinical settings. System replaces damaged hip joints to restore function and reduce pain. Benefits include mechanical stabilization of the hip joint in patients with degenerative, inflammatory, or traumatic conditions. Operates as a passive orthopedic implant; no electronic or software components.
Clinical Evidence
No clinical data. Bench testing only. Performance verified via range of motion analysis, component connection strength, fretting corrosion testing, burst strength, fatigue and post-fatigue testing on ceramic heads, and rim impingement evaluation. Device validated as non-pyrogenic.
Technological Characteristics
Modular femoral heads (alumina matrix per ISO 6474-2) and taper sleeves (Ti6Al4V per ISO 5832-3). Features 12/14 inner and 16/18 outer tapers. Designed for cementless fixation. Passive orthopedic implant; no energy source or software.
Indications for Use
Indicated for patients requiring hip joint replacement due to non-inflammatory degenerative joint disease (osteoarthritis, avascular necrosis), inflammatory joint disease (rheumatoid arthritis), functional deformity (congenital hip dysplasia), traumatic injury (traumatic arthritis, femoral head/neck fracture), or failed previous hip surgery (fixation, fusion, reconstruction, hemi-arthroplasty, surface/total replacement). Requires sufficient bone stock. Cementless fixation only.
Regulatory Classification
Identification
A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.
Predicate Devices
- Zimmer's Biolox Option Femoral Head and Taper Sleeve (K073567)
- Signature Orthopaedics' Evolve UniPolar Head and Taper Sleeve (K143184)
- Signature Orthopaedics' Signature Ceramic Head (K190704)
Reference Devices
- Signature Origin Stem (K121297)
- Signature Evolve Stem (K133370)
- Signature Orthopaedics NOOSA, NAMBUCCA and CAIRNS Lumbar Plate System (K163625)
- Signature World Hip System (K201278)
- TSI Stem (K102172)
- Origin Stem (K161155)
- Aria Stem (K121297)
- Remedy Stem (K133370)
- Spartan Stem (K192883)
- Logical Cup (K121297, K153131)
- Logical Liners (K121297)
- Logical 20deg Hooded Liners (K153131)
- World Cup (K201278)
- World Liner (K201278)
- Zimmer's Biolox Option Taper Sleeve (K093363)
Related Devices
- K150576 — TGM Biolox delta Ceramic Heads · Tgm Medical, Inc. · Sep 9, 2015
- K103431 — COREN TOTAL HIP SYSTEM · Corentec Co., Ltd. · Jul 21, 2011
- K071082 — STRYKER MODULAR HIP SYSTEM · Howmedica Osteonics Corp. · Sep 13, 2007
- K092406 — ABG II MODULAR HIP STEM · Howmedica Osteonics Corp. · Nov 4, 2009
- K081044 — REJUVENATE MODULAR HIP SYSTEM · Howmedica Osteonics Corp. · Jun 3, 2008
Submission Summary (Full Text)
{0}------------------------------------------------
April 16. 2021
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" in a square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION".
Signature Orthopaedics Pty Ltd. Declan Brazil Managing Director 7 Sirius Road Lane Cove, NSW 2066 Australia
Re: K201047
Trade/Device Name: Fusion Taper System Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, MEH, MBL Dated: March 15, 2021 Received: March 19, 2021
Dear Declan Brazil:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Vesa Vuniqi Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# INDICATIONS FOR USE STATEMENT
510(k) Number (if Known): K201047
Device Name: Fusion Taper System
Indications For Use:
Signature Orthopaedics' Fusion Taper System is intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for:
- . Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis
- . Inflammatory joint disease including rheumatoid arthritis
- . Correction of functional deformity including congenital hip dysplasia
- . Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture
- . Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemi-arthroplasty, surface replacement, or total replacement
Signature Orthopaedics' Fusion Taper System is intended for cementless fixation only.
Prescription Use: Yes (Part 29 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use: No (Part 29 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
{3}------------------------------------------------
______________________________________________________________________________________________________________________________________________________________________________
#### 2 510(K) SUMMARY
| Manufacturer: | Signature Orthopaedics Pty Ltd<br>7 Sirius Road<br>Lane Cove, NSW 2066<br>Australia |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Signature Orthopaedics Europe Ltd<br>Unit A, IDA Business & Technology Park Garrycastle<br>Athlone Westmeath N37 DY26<br>IRELAND |
| Device Trade<br>Name: | Fusion Taper System |
| Common Name: | Hip Replacement Prosthesis |
| Contact: | Dr. Declan Brazil |
| | Managing Director of Signature Orthopaedics |
| Prepared By: | Signature Orthopaedics Pty Ltd<br>7 Sirius Road<br>Lane Cove, NSW 2066<br>Australia<br>Phone: +61 (2) 9428 5181<br>Fax: +61 (2) 8456 6065 |
| Date Prepared: | 15th of March, 2021 |
| Classification: | Class II per 21 CFR 888.3353: Hip joint metal/ceramic/polymer<br>semi-constrained cemented or non-porous uncemented<br>prosthesis (MEH) |
| | Class II per 21 CFR 888.3353: Hip joint metal/ceramic/polymer<br>semi-constrained cemented or non-porous uncemented<br>prosthesis (LZO) |
| | Class II per 21 CFR 888.3358: Hip joint metal/polymer/metal<br>semi-constrained porous-coated uncemented prosthesis (MBL) |
| Predicate<br>Devices: | Primary Predicates<br>● Zimmer's Biolox Option Femoral Head and Taper<br>Sleeve (K073567) |
| | Secondary Predicates<br>● Signature Orthopaedics' Evolve UniPolar Head and<br>Taper Sleeve (K143184)<br>● Signature Orthopaedics' Signature Ceramic Femoral<br>Head (K190704) |
{4}------------------------------------------------
Reference Devices
- . Signature Origin Stem (K121297)
- . Signature Evolve Stem (K133370)
- . Signature Orthopaedics NOOSA, NAMBUCCA and CAIRNS Lumbar Plate System (K163625)
- . Signature World Hip System (K201278)
# Device Description:
The Fusion Taper System consists of modular femoral heads and taper sleeves. The Fusion Taper Sleeve is manufactured from Ti6Al4V as per ISO 5832-3. The Fusion Ceramic Head is manufactured from an alumina matrix as per ISO 6474-2. All Fusion Heads are intended for total hip arthroplasty. The Fusion Heads connect to the femoral stem via a Fusion Taper Sleeve which has a 12/14 inner taper and 16/18 outer taper. Signature Orthopaedics Fusion Taper System is indicated for use with Signature Ti6A14V femoral stems: TSI Stem (K102172), Origin Stem (K121297. K161155), Aria Stem (K121297), Remedy Stem (K133370), Spartan Stem (K192883), World Stem (K201278), and acetabular components: Logical Cup (K121297, K153131), Logical Liners (K121297), Logical 20deg Hooded Liners including lateralised variants (K153131), World Cup (K201278), and World Liner (K201278).
### Indications for Use:
Signature Orthopaedics' Fusion Taper System is intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for:
- · Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis
· Inflammatorv joint disease including rheumatoid arthritis
· Correction of functional deformity including congenital hip dysplasia
· Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture
· Failed previous hip surgery including internal fixation or joint fusion. reconstruction, hemi-arthroplasty, surface replacement, or total replacement Signature Orthopaedics' Fusion Taper System is intended for cementless fixation only.
# Summary of Technological Characteristics:
The Fusion Taper Sleeve has the same indications for use, body contact, sterilization method as Signature Orthopaedics' Signature Evolve UniPolar Taper Sleeve (K143184). The Fusion Taper Sleeve has the same intended use, indications for use, and taper sleeve material and connection as Zimmer's Biolox Option Taper Sleeve (K093363).
The Fusion Ceramic Head has the same indications for use, body contact, sterilization method is manufactured from the same material, has the same articular surface as Signature Orthopaedics' Signature Ceramic Head (K190704). The Fusion Ceramic Head has the same intended use and taper sleeve material and connection as Zimmer's Biolox Option Femoral Head (K073567).
{5}------------------------------------------------
### Non-Clinical Performance Testing:
Non-clinical testing and engineering evaluations were conducted to verify that the performance of the Fusion Taper System is adequate for anticipated in-vivo use. Non-clinical testing carried out included:
- Range of motion analysis
- . Component connection strength
- . Fretting corrosion testing
- . Burst strength, fatigue and post-fatigue testing on the Fusion Ceramic Head
- . Rim impingement evaluation
The subject device has been validated as non-pyrogenic.
#### Substantial Equivalence Conclusion:
The subject devices are substantially equivalent to the predicate devices since it has the same intended use, indications for use, body contact, materials, design features, and sterilization. Non-clinical testing results support the substantial equivalence claim.